CORXEL raises up to $287m in Series D1 financing
The financing backs clinical development of oral GLP-1 candidate CX11 and other cardiometabolic programs.
Corxel Pharmaceuticals announced the completion of a Series D1 financing of up to $287 million on January 22, 2026. The syndicate included RTW Investments, SR One, TCG Crossover, RA Capital Management and other healthcare investors.
Proceeds support CX11’s ongoing U.S. Phase 2 study, planned global Phase 2 work in type 2 diabetes and preparations for Phase 3 trials. The oral small-molecule GLP-1 receptor agonist is the company’s lead obesity and diabetes candidate.
CORXEL also plans to advance its wider cardiometabolic pipeline and strengthen global clinical development operations. SR One, TCGX and certain other investors will appoint three new board representatives in connection with the financing.
Use of funds
Advance CX11 through U.S. and global Phase2 studies and prepare Phase3 trials
Develop other cardiometabolic clinical programs
Expand global clinical development operations